

# Adhesion molecules and inflammatory injury

STEVEN M. ALBELDA,\*<sup>1</sup> C. WAYNE SMITH,<sup>†</sup> AND PETER A. WARD<sup>‡</sup>

\*Pulmonary and Critical Care Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA; <sup>†</sup>Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA; and <sup>‡</sup>Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA

**ABSTRACT** Neutrophil-endothelial cell interactions are mediated by interacting sets of cell adhesion molecules (CAMs) and chemoattractant/activator molecules to form an "adhesion cascade." The initial phase of inflammation, a transient slowing of neutrophils in postcapillary venules, is mediated by selectins. Subsequently, firm adhesion of neutrophils to the vessel wall occurs via interaction of the CD11/CD18 ( $\beta_2$ ) integrins to endothelial ligands such as intercellular adhesion molecule-1 (ICAM-1). This binding requires activation of CD11/CD18 by exposure of the neutrophil to a variety of activating/chemoattractant molecules, such as platelet-activating factor or interleukin-8. Finally, transmigration into tissues occurs, a process that requires both a chemotactic stimulus and engagement of platelet-endothelial cell adhesion molecule-1 (PECAM-1). Several approaches have been used to probe the role of CAMs in vivo. These include the use of blocking antibodies, chimeric selectin-immunoglobulin proteins, sialyl Lewis<sup>x</sup> oligosaccharides and peptides, along with the study of humans and animals with genetically determined adhesion deficiencies. These studies demonstrate that CAM blockade can effectively inhibit inflammation; however, there appear to be clear differences in the adhesion requirements for particular types of inflammation. By understanding the CAM/chemoattractant profiles involved in specific disease states, it may be possible to precisely and effectively target therapy to a wide variety of inflammatory diseases.—Albelda, S. M., Smith, C. W., Ward, P. A. *Adhesion molecules and inflammatory injury. FASEB J.* 8: 504–512; 1994.

*Key Words:* adhesion molecules • inflammation • endothelial cells • leukocytes • integrins • selectins • immunoglobulin superfamily • neutrophils • cell adhesion

THE RECRUITMENT OF LEUKOCYTES INTO AREAS OF inflammation begins with the binding of white blood cells to endothelium, followed by their transmigration into tissues. Although this observation has been documented for more than 150 years, only in the last decade, with the identification of specific cell adhesion and chemoattractant/activator molecules, have the molecular mechanisms underlying leukocyte adhesion been uncovered. Three families of cell adhesion molecules (CAMs)<sup>2</sup> play a central role in leukocyte-endothelial interactions: the selectins, the integrins, and the immunoglobulin superfamily (1) (see Table 1). In addition, factors that activate neutrophils or endothelial cells (Table 2), thereby resulting in CAM expression and/or chemotactic migratory responses, are also important. It is now recognized that these different types of CAMs and chemoattractants interact in a programmed, sequential manner to form what has been termed the leukocyte-endothelial cell adhesion cas-

cade (2–5). The purpose of this review is to summarize recent information concerning the mechanisms by which leukocytes (specifically, neutrophils) enter regions of inflammation and how this information might be used to develop novel therapeutic approaches.

## THE ENDOTHELIAL CELL-LEUKOCYTE ADHESION CASCADE

Most neutrophil emigration occurs in specialized regions of the vascular tree, i.e., in postcapillary venules, and can be divided into distinct phases (Fig. 1). When viewed with *in vivo* microscopy (reviewed in ref 6), the first event (Fig. 1B) is the slowing or margination of the circulating leukocytes within the venule where the white cells are only loosely tethered to the vessel wall and roll along the surface of the endothelium at velocities of less than 50  $\mu\text{m/s}$ . After a variable period of rolling, many neutrophils firmly adhere to the endothelial cell surface (Fig. 1C) and appear to become activated, changing from a spherical configuration to a flattened shape. Aggregates of neutrophils and some attached platelets are often seen. Adherent cells then migrate through the junctions of endothelial cells and move to a region between the endothelium and its basement membrane (Fig. 1D). After a brief pause in this location, the neutrophils finally migrate into the surrounding interstitial tissue. Each step of neutrophil emigration has been associated with specific CAMs and CAM activators or chemoattractants.

### Rolling

The initial phase of the adhesion cascade, neutrophil rolling, is mediated by members of the selectin family. The selectins (7, 8) include a group of three related molecules. L-selectin (Lam-1, LECAM-1) is constitutively expressed on neutrophils and is shed from the cell surface on cell activation, assumed to occur immediately after rolling begins (9). P-selectin (GMP140 or PADGEM) is found on platelets and is stored in Weibel-Palade bodies where it is quickly (within minutes) moved to the cell surface after endothelial cell activation by stimuli such as histamine, thrombin, bradykinin, leukotriene C<sub>4</sub> (LTC<sub>4</sub>), or free radicals. E-selectin (ELAM-1)

<sup>1</sup>To whom correspondence should be addressed, at: 809 Maloney Bldg./H. U. P., 3600 Spruce St., Philadelphia, PA 19104, USA.

<sup>2</sup>CAM, cell adhesion molecule; PECAM-1, platelet-endothelial cell adhesion molecule; Ig, immunoglobulin; TNF $\alpha$ , tumor necrosis factor- $\alpha$ ; IL-1, interleukin 1; LFA-1, lymphocyte function antigen-1; PAF, platelet activating factor; IL-8, interleukin 8; ICAM, intercellular adhesion molecule; VCAM-1, vascular cell adhesion molecule-1; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; LAD, leukocyte adhesion deficiency; LPS, lipopolysaccharide.

TABLE 1. *Leukocyte-endothelial cell adhesion receptors*

Molecule	Primary expression	Ligand
<b>Selectins</b>		
L-selectin	PMN and lymphs	CD34, GlyCAM-1 <sup>a</sup>
P-selectin	EC, platelet	P-selectin glycoprotein ligand (PSGL-1) Sialyl Lewis <sup>x</sup> and others
E-selectin	EC	Sialyl Lewis <sup>x</sup> and others
<b>Integrins</b>		
LFA-1 (CD11a/CD18)	PMN and lymphs	ICAM-1 and ICAM-2
Mac-1 (CD11b/CD18)	PMN	ICAM-1, and others <sup>b</sup>
VLA-4 ( $\alpha_4\beta_1$ Integrin)	Eos and lymphs	VCAM-1, FN
<b>Immunoglobulin superfamily</b>		
ICAM-1	Lymphs and EC	LFA-1, Mac-1
ICAM-2	Lymphs and EC	LFA-1
VCAM-1	EC	VLA-4
PECAM-1	EC, PMN, lymphs, platelets	PECAM, others

<sup>a</sup>Ligands for lymphocyte L-selectin; the ligands for neutrophil L-selectin have not yet been identified. <sup>b</sup>Other ligands for Mac-1 include iC3b, fibrinogen, and bacterial LPS. PMN, polymorphonuclear leukocyte; lymphs, lymphocytes; EC, endothelial cells; Eos, eosinophils.

is expressed solely on endothelial cells where it is synthesized rapidly after cell stimulation by cytokines (TNF $\alpha$ , IL-1) or endotoxin and then translocated to the luminal surface of the venular endothelium.

Each selectin shares a common molecular structure, most notably an NH<sub>2</sub>-terminal lectin-like domain, that imparts the ability of each selectin to bind to specific carbohydrate ligands. To date, three structures have been identified that appear to have binding affinity for selectins: 1) oligosaccharides related to sialyl Lewis<sup>x</sup> and sialyl Lewis<sup>a</sup>; 2) phosphorylated mono- and polysaccharides; and 3) sulfated polysaccharides and lipids (7). It is still unclear which molecules (in the form of glycoconjugates) present these carbohydrate derivatives to the selectins as counter-receptors. Although ligands for lymphocyte L-selectin on high endothelial venules have been identified and cloned (10), a similar ligand for neutrophil L-selectin on activated endothelium has yet to be


identified. One function of L-selectin may be to present molecules of sialyl-Lewis<sup>x</sup> to E-selectin and P-selectin and thus to serve as one of the counter receptors for selectins on endothelial cells and platelets (11, 12). Recently, Sato et al. (13) used expression cloning to identify a mucin-like transmembrane glycoprotein that functions as a ligand for P-selectin on myeloid cells when appropriately glycosylated (termed P-selectin glycoprotein ligand or PSGL-1).

#### Activation and firm adhesion

Although rolling appears to be a prerequisite for eventual firm adherence to blood vessels under conditions of flow (14), selectin-dependent adhesion of leukocytes does not lead to firm adhesion and transmigration unless another set of adhesion molecules is engaged. For neutrophils, firm adhesion requires activation of the  $\beta_2$  (CD18) integrin family, resulting

TABLE 2. *Neutrophil and endothelial cell activating factors*

Activating agent	Targets	
	Neutrophils	Endothelial cells
<b>Cytokines</b>	Tumor necrosis factor $\alpha$ (TNF $\alpha$ ) Interleukin-1 (IL-1)	TNF $\alpha$ IL-1 Interleukin-4 Interferon- $\gamma$
<b>Chemokines</b>	Interleukin-8 GRO $\alpha$ Neutrophil-activating peptide-2 Platelet factor 4	
<b>Lipids</b>	Leukotriene B <sub>4</sub> (LTB <sub>4</sub> ) Platelet-activating factor (PAF) Bacterial endotoxin	
<b>Other</b>	Complement fragments (C5a) f-Met-Leu-Phe (FMLP)	Thrombin Histamine H <sub>2</sub> O <sub>2</sub> Bradykinin Leukotriene C <sub>4</sub> (LTC <sub>4</sub> )



**Figure 1.** The endothelial cell-leukocyte adhesion cascade. Under baseline conditions (A), neutrophils are nonadherent to the vessel wall. The first event in white cell emigration is the slowing or rolling of the circulating leukocytes within the venule mediated by selectins (B). After a variable period of rolling, an activation event occurs resulting in neutrophils firmly adhering to the endothelial cell surface (C) and changing from a spherical configuration to a flattened shape. This process requires interaction of activated CD18 integrins on neutrophils with immunoglobulin superfamily members (i.e., ICAM-1) on the endothelium. Adherent cells then transmigrate through the junctions of endothelial cells (D), an event that requires a chemotactic gradient and involvement of the adhesion molecule, PECAM-1. After a brief pause in this location, the neutrophil finally migrates into the surrounding interstitial tissue.

in binding to one of the intercellular adhesion molecules on the surfaces of endothelial cells.

The CD11/CD18 integrins, specifically CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1), were among the first cell adhesion molecules to be identified and characterized (14, 15). As typical members of the integrin family, these molecules are heterodimers composed of unique  $\alpha$  subunits noncovalently bound to a common  $\beta$  subunit ( $\beta_2$ ) (1). Although both CD11a and CD11b interact with the immunoglobulin superfamily member, ICAM-1, CD11b is capable of binding a wide range of ligands, including fibrinogen, denatured albumin, and complement fragments (iC3b) (16), as well as unidentified ligands on endothelial cells (17).

An important characteristic of the neutrophil integrins is that under baseline conditions they exist in a relatively inactive conformation, rendering the leukocyte nonadhesive. One of the key events of the adhesion cascade is the activation (sometimes accompanied by the addition of protein on the cell surface) and deactivation of these integrins at the proper times and places. Evidence for a conformational change associated with high avidity is found in the binding of some monoclonal antibodies that appear to recognize epi-

topes found only in the activated or bound state of the integrins (18, 19).

One important pathway by which integrin activation appears to occur is that neutrophils interact with stimulatory molecules that are bound to the surface of the endothelium. This idea is attractive for several reasons. First, it explains how chemoattractants could act quickly enough to target leukocyte migration before being swept downstream. Second, most of the chemoattractant molecules, in addition to activating integrins, also cause shedding of L-selectin and stimulate neutrophil locomotion. Kishimoto et al. (9) proposed that shedding of L-selectin may facilitate cell migration by releasing a potentially tethering adhesive mechanism as neutrophils shift to  $\beta_2$  integrin-dependent migration. Location and timing of this stimulation may be critical as, in fact, many chemoattractant molecules have well-documented leukocyte adhesion inhibitory activity when presented to neutrophils in soluble phase (20).

Good evidence to support the importance of surface activation in white cell emigration has been presented for two inflammatory mediators: platelet-activating factor (PAF) and interleukin-8 (IL-8). PAF is synthesized by endothelial cells within minutes after stimulation by thrombin, histamine, LTC<sub>4</sub>, or other agonists, and is expressed on the cell surface where it activates neutrophils and up-regulates CD11b by binding to a specific cell-surface receptor (21). Many of the same factors that stimulate PAF expression also cause rapid translocation of P-selectin to the surface of the endothelium (see above). Thus, for at least one set of stimuli both a specific tethering molecule (P-selectin) and a specific activator molecule (PAF) are produced. A similar situation may exist for the neutrophil chemoattractant/activator IL-8. IL-8 appears to bind to the luminal surface of activated endothelial cells where it is able to activate neutrophils (22). Because cytokines, such as TNF $\alpha$ , and other factors (such as endotoxin) cause the synthesis of both IL-8 and E-selectin from endothelial cells (23), it is likely that these mediators may augment neutrophil transmigration by stimulating expression of both the tethering molecule and the activating factor (24).

Important ligands for the CD11/CD18 integrins are ICAM-1, and possibly ICAM-2 (reviewed in ref 21). These molecules, members of the immunoglobulin superfamily, are present constitutively on endothelial cells both *in vitro* and *in vivo*. CD11a and CD11b bind to ICAM-1 in different regions of the molecule. Only CD11a has been shown to be capable of binding to ICAM-2. Constitutive expression of endothelial ICAM-2 is relatively stable, whereas ICAM-1 expression can be augmented by a variety of inflammatory mediators including TNF, IL-1,  $\gamma$ -interferon, and endotoxin. The increase in expression is dependent on protein synthesis and peaks about 8 h after stimulation in both *in vitro* (2) and *in vivo* models (25). Monoclonal antibody blocking experiments suggest that ligands in addition to ICAM-1 may be important in neutrophil-endothelial interactions (5, 26). Even with the relatively high levels of ICAM-1 on resting endothelium, it appears that the additional expression induced by cytokines is important in neutrophil-endothelial interactions.

### Transmigration

Transendothelial cell migration does not necessarily accompany leukocyte adherence to the endothelium. Although chemotactic factors, such as LTB<sub>4</sub>, C5a, and f-Met-Leu-Phe, can augment leukocyte adhesion to endothelium (reviewed in ref 27), transmigration across an endothelial monolayer requires a chemotactic gradient (28). Spontaneous trans-

migration of neutrophils through TNF $\alpha$ - or IL-1-stimulated endothelial monolayers has been observed (29, 30); however, it is likely that these cytokines also cause expression of potent chemotactic stimuli such as IL-8 (24), which for the reasons cited above, affect both adherence and transmigration of neutrophils.

Recent studies have implicated another adhesion molecule, platelet-endothelial cell adhesion molecule-1 (PECAM-1), in transmigration. PECAM-1, a member of the immunoglobulin superfamily, is expressed at relatively low levels on the surface of leukocytes and platelets but at higher levels ( $>10^6$  molecules per cell) on endothelium (31). Its localization at the junctions between endothelial cells has suggested a role in transendothelial cell migration. Using an *in vitro* model, Muller et al. (30) demonstrated that antibodies against PECAM-1 significantly blocked leukocyte transmigration through TNF $\alpha$ -activated endothelial cell monolayers but did not affect the adhesion of neutrophils. This effect has recently been confirmed in animal models of neutrophil transmigration (32). The mechanisms by which PECAM-1 may regulate transendothelial migration are not yet known; however, the possibilities include direct binding of PECAM-1 to the leukocyte (perhaps serving as a molecular guide as it passes through the junction), or regulation of adhesion molecules on the surface of the leukocyte (i.e.,  $\beta_2$  integrins), thus facilitating transmigration (30). Available data indicate that cross-linking of PECAM-1 on the surface of leukocytes by antibodies can up-regulate integrin-mediated binding (33).

Another process that may play an important role in transendothelial migration is the ability of the endothelial cell monolayer to regulate an opening of its junctions, allowing neutrophil transmigration. Recent work by Huang et al. (34) suggests that transmigrating neutrophils (in response to a chemotactic stimulus) exert an active influence on the endothelial cell monolayer, resulting in increased intracellular endothelial calcium levels and opening of intercellular junctions.

#### NONCASCADE DEPENDENT LEUKOCYTE EMIGRATION

As a general rule, neutrophil transmigration appears to be preceded by endothelial activation (defined by up-regulation of adhesion molecules). However, this cascade may not be operative during all types of inflammatory reactions. Several chemoattractant/activators are able to directly up-regulate neutrophil CD11b/CD18 activity and allow adhesion of the leukocytes to resting, unactivated endothelial cells (perhaps by binding to constitutively expressed ICAM-1) without apparent involvement of selectins. This process is also probably operative *in vivo* (4). It thus seems likely that in vascular beds where blood flow is diminished (by geometric constraints or by vascular occlusion/vasoconstriction), activation of the CD18 integrins, along with the presence of a chemotactic gradient, may be sufficient for neutrophil transmigration, without additional activation of endothelium. This mechanism may be operative in clinical situations, such as sepsis, where intravascular activation of neutrophils leads to neutrophil sequestration in the lung and other organs.

Another process that may be an accessory means of localizing additional neutrophils at the early stages of inflammatory reaction is neutrophil aggregation. This represents both homotypic aggregation between neutrophils, a phenomenon that has been shown *in vitro* to be primarily a CD11b-dependent event (35), and heterotypic aggregation between neutrophils and platelets, an event primarily dependent on P-selectin, at least *in vitro* (36).

#### INFLAMMATION AND THE ADHESION CASCADE

Because of the complexity and diversity of the inflammatory response, it has been increasingly important to evaluate the role of cell adhesion molecules in animal models of specific inflammatory events. Probing the role of adhesion molecules involved in *in vivo* inflammatory responses has taken several different approaches. One strategy has been to infuse soluble forms of CAMs to compete with naturally occurring *in vivo* selectin molecules and inhibit neutrophil accumulation (37, 38). These studies have, for the most part, used chimeric selectin-Ig proteins (which contain the extracellular portions of selectins fused to the CH2 and CH3 domains of the IgG heavy chain), as these hybrids have a longer half-life than soluble forms of selectins when infused intravenously. The infusion of an L-selectin chimera significantly inhibited the number of neutrophils migrating to the peritoneum in response to an inflammatory infiltrate (37). In rat models, L- and P-selectin chimeras blocked complement-mediated lung injury, whereas L- and E-selectin chimeras inhibited immune complex-induced lung damage (38). A related strategy, shown to be useful in the case of either E-selectin or P-selectin-dependent inflammatory reactions, involves the infusion of sialyl Lewis<sup>x</sup> oligosaccharides (the penta and tetra versions) that appear to compete with selectin-dependent binding interactions (39). It may also be possible to design peptides that simulate the binding site of an adhesion molecule. To date, this has been chiefly used to interfere with P-selectin (40) or CD11b-dependent reactions *in vitro* (41). The applicability of these peptides *in vivo* remains to be determined.

Another approach that has yielded a great deal of information about the *in vivo* role of adhesion molecules has been the study of animals (or humans) in which there is a naturally occurring or artificially induced CAM defect. Some of the earliest clues suggesting the clinical importance of cell adhesion molecules came from the study of congenitally acquired syndromes featuring impaired host defenses against bacterial pathogens. Leukocyte adhesion deficiency (LAD) type I (reviewed in ref 15) is characterized by a profound defect in phagocyte emigration, chronic neutrophilia, and recurrent infections without formation of pus, and is due to a deficiency of members of the CD11/CD18 family of adhesion molecules on neutrophils as a result of a number of different mutations. Neutrophils isolated from LAD-type I patients show normal rolling behavior, but are incapable of sticking to endothelial monolayers or emigrating in response to chemotactic stimuli. The recently described LAD-type II (42) is characterized by a very similar clinical scenario; however, molecular analysis has revealed that this syndrome is due to a congenital defect of endogenous fucose metabolism. This results in an inability to synthesize fucosylated carbohydrate molecules, such as sialyl Lewis<sup>x</sup>, and a crippled selectin system. Consistent with predictions, neutrophils isolated from LAD type II patients are able to adhere normally to activated endothelial monolayers under static conditions but show marked defects in rolling and adherence under shear force (43).

More recently, it has been possible to begin to explore the role of leukocyte-endothelial cell molecules in inflammation by studying mice engineered using homologous recombination techniques to lack specific CAMs. Wilson et al. (44) have developed mice that express only 2–16% of the normal levels of CD18 expression on granulocytes. These animals show an impaired inflammatory response to a chemical peritonitis and delayed rejection of cardiac grafts. "Knock-

outs" of two of the immunoglobulin superfamily cell adhesion molecules have also recently been achieved. Mice deficient in VCAM-1 expression are not viable and die in utero due to cardiac and other developmental abnormalities (45). In contrast, mice deficient in ICAM-1 (46) develop normally, are fertile, and appear normal except for a moderate granulocytosis. However, these ICAM-1-deficient animals exhibit impaired neutrophil emigration in response to chemical peritonitis and decreased contact hypersensitivity to 2,4-dinitrobenzene. In addition, leukocytes from these mice provide negligible stimulation for the mixed lymphocyte reactions. Mice lacking P-selectin (47) develop normally; however, they exhibit a striking leukocytosis, diminished rolling of leukocytes in mesenteric vessels, and delayed recruitment of neutrophils to the peritoneal cavity after experimentally induced peritonitis. E-selectin-deficient mice (45) have a similar phenotype with regard to delay in neutrophil recruitment into experimentally induced peritonitis, but do not have leukocytosis. Administration of anti-P-selectin antibody to the E-selectin knockout mice completely blocks neutrophil recruitment, suggesting that in this model some redundancy of function may exist between the two endothelial cell selectins. The degree of immune deficiency in most of the knockout animals is not as severe as in humans and bovines with the severe form of LAD I deficiency who naturally acquire acute life-threatening bacterial infections at an early age. Early deletion of a specific CAM may allow alternative pathways to develop. A significant problem in evaluation of the gene knockout animals maintained in barrier facilities is the need to apply highly quantitative and reliable techniques for the *in vivo* measurement of possible changes in expression of the inflammatory response.

Much of our knowledge about the role of CAMs in inflammation has come from the use of blocking antibodies. This approach has not been entirely straightforward, however, because of the inability of many well-characterized blocking antibodies to cross-react in animal species, the tendency of some antibodies (i.e., anti-L-selectin) to induce neutropenia, and interactions by the Fc portion of some antibodies necessitating the use of F(ab')<sub>2</sub> fragments (48). Nevertheless, these difficulties have been solved in different ways, including careful screening of known bioactive human monoclonal antibodies against a variety of animal species and looking for cross-reactivity (e.g., ref 48), the generation of rodent-specific bioactive antibodies, and by transplantation of human tissues into immunodeficient mice (25).

### Selectins

The role of L-selectin in neutrophil transmigration *in vivo* was first demonstrated by Jutila et al. (49), who showed that an antibody (MEL-14) against the murine form of L-selectin could suppress neutrophil accumulation within the inflamed peritoneum of a mouse by about 70%. Ley et al. (50), using intravital microscopy, directly demonstrated a decrease in the number of neutrophils undergoing rolling within rat mesenteric venules after administration of a polyclonal anti-L-selectin antibody.

Despite a great deal of *in vitro* work indicating that E-selectin is important in neutrophil-endothelial cell adhesion (reviewed in ref 7), the lack of cross-reacting antibodies has limited *in vivo* experiments. There are only a few reports demonstrating blockade of white cell emigration by inhibition of E-selectin function in an intact animal. Mulligan et al. (48) were able to block neutrophil migration into glycogen-induced peritoneal exudates and immune complex-induced skin and lung inflammation with a murine anti-

human E-selectin antibody discovered to cross-react with rat E-selectin. Gundel et al. (51) were able to inhibit the influx of neutrophils associated with the late-phase airway inflammation in a primate model. Antibodies against human E-selectin have recently been used to block white cell emigration in TNF $\alpha$ -activated human skin transplanted onto SCID mice (52).

Similar problems with appropriate cross-reacting bioactive antibodies have also hindered the understanding of the physiologic role of P-selectin. Recently, however, inflammatory reactions that appear to depend heavily on P-selectin interactions have been identified. These include pulmonary vascular injury secondary to intravenous complement activation (53) and ischemia/reperfusion injury (54, 55).

### CD11/CD18

The development of monoclonal antibodies with the ability to block CD11a, CD11b, and/or CD18 function in animals without causing neutropenia has allowed many experiments to be performed examining the role of CD18 in inflammation (the reader is referred to several excellent reviews [5, 6] that discuss this topic in detail). Of all the adhesion molecules studied to date, CD18 seems to have the most wide-ranging and powerful effects. Blockade of the CD11/CD18 complex has been shown to inhibit neutrophil influx in almost every system tested to date, including skin, peritoneum, synovium, lung, kidney, and heart. Accordingly, intravenous application of anti-CD11/CD18 antibodies have been shown to reduce inflammation and injury in models of allograft rejection, endotoxic and hemorrhage shock, hypersensitivity reactions, bacterial meningitis, aspiration lung injury, pneumonia, and ischemia reperfusion. There are a few examples where both CD18-dependent and CD18-independent pathways of neutrophil emigration have been identified, including certain types of lung inflammation (56) and the late movement of neutrophils into inflamed peritoneum (57).

### ICAM-1

As one of the primary ligands for the CD18 integrins, it would be expected that blockade of ICAM-1 would inhibit the inflammatory response. Some studies (again, see ref 6 for review) have shown effects of ICAM-1 antibodies in various models of inflammation such as transplant rejection, delayed hypersensitivity, asthma, ischemia/reperfusion, and immune complex injury.

### CELL ADHESION MOLECULE INVOLVEMENT DEPENDS ON THE ORGAN AND THE NATURE OF THE INFLAMMATORY STIMULUS: LESSONS FROM INFLAMMATORY ANIMAL MODELS

One of the most important lessons that has emerged from animal studies of CAMs is that there are distinct differences in the adhesion requirements for particular types of inflammation. This point is clearly illustrated by comparing a series of studies by Mulligan et al. (38, 39, 48, 53, 58-62) conducted in well-characterized rat models of inflammation. In these experiments, summarized in Table 3, the effects of bioactive antiadhesion molecule antibodies or selectin-Ig chimeras on the intensity of tissue injury in four different models of inflammation are compared. Whereas anti-CD18 antibodies are effective in blocking all forms of neutrophil-dependent inflammation, there seem to be differential contributions of CD11a vs. CD11b. Another interesting difference is that the selectin requirements of various inflamma-

TABLE 3. Differences in cell adhesion requirements in rat models of inflammation

Inflammatory model	Reduction (%) in Inflammatory Injury by antibody or selectin-chimera blockade*						
	P-selectin	E-selectin	CD18	CD11a	CD11b	ICAM-1	VLA-4
IgG immune complex lung injury	0	95	71	63	15(n. s.)	61	40
IgA immune complex lung injury	5(n. s.)	11(n. s.)	89	36	63	61	77
Systemic complement activation-related lung injury (CVF)	47	0	69	30	53	72	0
IgG immune complex-induced glomerulitis	0	0	64	0	46	55	37

\*As measured by vascular permeability or hemorrhage in the case of lung injury and proteinuria (24 h) in the case of glomerulonephritis. Except as designated by n. s. (not significant), all values were statistically significant ( $P < 0.05$ ). See refs 38, 39, 48, 53, 58-62 for details.

tory models, even within the same organ system, are quite different. For example, E-selectin expression is up-regulated in the pulmonary vasculature after intratracheal instillation of lipopolysaccharide (LPS), IL-1, TNF $\alpha$ , or deposition of IgG immune complexes (Fig. 2). Accordingly, antibodies to E-selectin blocked neutrophil influx and tissue injury in IgG immune complex-mediated lung disease (48). However, anti-E-selectin antibodies had no effect on IgA-mediated immune complex lung disease, a model where tissue macrophages seem to play a dominant role (59). It is hoped that as more models of injury are carefully studied, a set of rules will emerge that will define which combination of cell adhesion molecules, cytokines, and chemoattractants is involved in specific disease states.

#### THERAPEUTIC APPROACHES

Interruption of the leukocyte-endothelial cell cascade has become a major focus of anti-inflammatory research. Several approaches are being developed. The blockade of CAM function by use of specific blocking monoclonal antibodies is one strategy. For example, anti-LFA-1 monoclonal antibodies have been used to prevent graft failure in patients receiving HLA-mismatched bone marrow transplants (63). Clinical trials are currently under way using anti-ICAM-1 antibodies to inhibit kidney allograft rejection (64). Obviously, the use of monoclonal antibodies in the treatment of human diseases will be limited by the generation of antimurine antibodies by the recipient. However, the use of monoclonal antibodies may be useful for problems that would benefit from short-term therapies, such as acute transplant rejection, prevention of ischemia reperfusion injury, or in well-defined episodes of sepsis or tissue injury. Humanization of murine antibodies may provide some advantage by limiting the production of antimurine antibodies.

Because of problems such as immunogenicity, the potential for causing immune complex disease, and requirements for intravenous administration, a number of alternative ways to inhibit cell adhesion molecules, are being explored. Soluble forms of adhesion molecules represent one such approach. Neutrophil influx has been inhibited in vitro with soluble P-selectin (65) and in murine and rat models using soluble selectin-IgG chimeras (37, 38). Unfortunately, the bioactivity of other soluble recombinant adhesion receptors, E-selectin for example (66), seems to be quite low. The difficulty in preparing large quantities of these receptors and the requirement for intravenous delivery further limit their potential utility. As mentioned above, the creation of peptide mimetics of active binding regions of CAMs is also being explored. Short peptides based on sequences of ICAM-1 (41, 67), P-selectin (40), and PECAM-1 (68) have been shown to

block certain in vitro adhesion events and could potentially be useful in animal models.


Of more practical use would be small molecular weight compounds with the potential for oral administration. The discovery that selectin-mediated adhesion is dependent on carbohydrate binding has generated a great deal of interest in creating bioactive and biostable analogs of sialyl-Lewis<sup>x</sup> or related sugars (see ref. 69 for example). Recent work in rat models of inflammation (39) have demonstrated the therapeutic feasibility of this strategy. Another approach that holds promise is the use of antisense oligonucleotides directed at cell adhesion molecules. Bennett et al. (70) have been able to design oligonucleotides that selectively inhibit the expression of ICAM-1, VCAM-1, and E-selectin in human endothelial cells, as well as block leukocyte adhesion to TNF-stimulated endothelium in vitro. Preliminary studies indicate that an antisense oligonucleotide directed toward murine ICAM-1 exhibits anti-inflammatory activity in several mouse models of inflammation (71).

Finally, several agents appear to inhibit integrin-mediated white cell adhesion by unknown mechanisms. A partial listing of such compounds would include PGE<sub>1</sub> (72), lipoxin A (73), nitric oxide (74), adenosine (75), and dapsone (76). One of the most promising new families of molecules are the leumedins, a new class of anti-inflammatory compounds whose only known mechanisms of action to date is blockade of integrin  $\beta_2$  function (77). One of these compounds has been effective in increasing survival in endotoxin-treated mice (78). The clinical applications of these new therapeutics, along with agents designed to inhibit chemoattractant molecules and cytokines (79), will doubtlessly be tested in the near future.

#### CONCLUSIONS

Our understanding of the mechanisms of leukocyte emigration into areas of inflammation has increased dramatically in the past decade. New adhesion molecules have been identified. The physiological and pathophysiological roles played by these molecules are rapidly being determined, along with the realization that certain subsets of adhesion molecules may be important in specific forms of inflammation. The complex relationships between adhesion molecules, cytokines, and chemoattractants are also of active interest.

This knowledge has generated expectations that strategies designed to inhibit cell adhesion will lead to novel and clinically useful forms of anti-inflammatory treatments. This goal is likely to be realized first in acute, self-limited disorders amenable to treatment by intravenous infusion, such as ischemia/reperfusion injury or early organ transplant rejection. By understanding the precise CAM/chemoattractant



**Figure 2.** Pulmonary vascular expression of E-selectin. Panels *A-D* represent immunoperoxidase staining of frozen sections of rat lung for E-selectin using a cross-reacting anti-human E-selectin monoclonal antibody. Normal lung (*A*), lungs after intratracheal instillation of lipopolysaccharide (*B*), murine IL-1 (*C*), and murine TNF $\alpha$  (*D*). Panels *E* and *F* are rat pulmonary artery endothelial cells in culture stained for E-selectin: untreated endothelial cells (*E*); endothelial cells treated for 4 h with TNF $\alpha$  (*F*). (*A-D*,  $\times 200$ ; *E*, *F*,  $\times 400$ ) (Mulligan, M. S., and Ward, P. A., unpublished results).

profiles involved in specific disease states, it may be possible to more precisely target therapy for use in long-term therapy. For example, if the combination of molecules that result in eosinophil infiltration were known, it might be possible to design a more effective therapy for asthma. Selective targeting of antiadhesion therapy to defined anatomic regions, such as delivery of a drug by inhalation or by instillation into

an affected joint space, could also be a useful alternative. Critically important will be the identification organ or disease-specific CAMs. Endothelial proteins that target subsets of lymphocytes to the skin or certain subsets of lymph nodes (80) have been recognized and raise the possibility that other such organ-specific homing receptors might also exist.

**FJ**

We thank Dr. J. Pilewsky for his careful reading of this manuscript and valuable suggestions, Ms. Jacqueline Schaffer for the artwork, and Ms. Vanessa Mack for skillful preparation of the manuscript. We would also like to apologize to all the authors of the many excellent studies not referenced in this review because of space limitations. This work was supported by National Institutes of Health grants HL49591 (S. M. A.), HL46311 (S. M. A.), HL31963 (P. A. W.), HL42550, AI23521, AI19031 (C. W. S.), and a grant from the Polly Annenberg Levee Charitable Trust (S. M. A.). S. M. A. is an Established Investigator of the American Heart Association.

## REFERENCES

- Albelda, S. M., and Buck, C. A. (1990) Integrins and other cell adhesion molecules. *FASEB J.* **4**, 2868-2880
- Pober, J. S., and Cotran, R. S. (1990) The role of endothelial cells in inflammation. *Transplantation* **50**, 537-544
- Butcher, E. C. (1991) Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. *Cell* **67**, 1033-1036
- von Andrian, U. H., Chambers, J. D., McEvoy, L. M., Bargatze, R. F., Arfors, K., and Butcher, E. C. (1991) Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte  $\beta_2$  integrins in vivo. *Proc. Natl. Acad. Sci. USA* **88**, 7538-7542
- Smith, C. W. (1993) Endothelial adhesion molecules and their role in inflammation. *Can. J. Physiol. Pharmacol.* **71**, 76-87
- Harlan, J. M., Winn, R. K., Vedder, N. B., Doerschuk, C. M., and Rice, C. L. (1992) In vivo models of leukocyte adherence to endothelium. In *Adhesion: Its Role in Inflammatory Disease* (Harlan, J. M., and Lui, D. Y., eds) pp. 117-150, Freeman and Company, New York
- Bevilacqua, M., and Nelson, R. M. (1993) Selectins. *J. Clin. Invest.* **91**, 379-387
- Lasky, L. A. (1992) Selectins: interpreters of cell-specific carbohydrate information during inflammation. *Science* **258**, 964-969
- Kishimoto, T. K., Jutila, M. A., Berg, E. L., and Butcher, E. C. (1989) Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. *Science* **245**, 1238-1241
- Baumhueter, S., Singer, M. S., Hanzel, W., Hemmerich, S., Renz, M., Rosen, S. D., and Lasky, L. A. (1993) Binding of L-selectin to the vascular sialomucin CD34. *Science* **262**, 4364-438
- Picker, L. J., Warnock, R. A., Burns, A. R., Doerschuk, C. M., Berg, E. L., and Butcher, E. C. (1991) The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP140. *Cell* **66**, 921-933
- Abbassi, O., Kishimoto, T. K., McIntire, L. V., Anderson, D. C., and Smith, C. W. (1993) E-Selectin supports neutrophil rolling in vitro under conditions of flow. *J. Clin. Invest.* **92**, 2719-2730
- Sato, D., Chang, X.-J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahern, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. (1993) Expression cloning of a functional glycoprotein ligand for P-selectin. *Cell* **75**, 1-20
- von Andrian, U. H., Hansell, P., Chambers, J. D., Berger, E. M., Filho, I. T., Butcher, E. C., and Arfors, K.-E. (1992) L-selectin function is required for beta-2 integrin-mediated neutrophil adhesion at physiologic shear rates in vivo. *Am. J. Physiol.* **263**, H1034-H1044
- Anderson, D. C., Schmalstieg, F. C., Finegold, M. J., Hughes, B. J., Rothlein, R., Miller, L. J., Kohl, S., Fosi, M. F., Jacobs, R. L., Shearer, W. T., and Springer, T. A. (1985) The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. *J. Infect. Dis.* **152**, 668-689
- Wright, S. D., Lo, S. L., and Detmers, P. A. (1990) Specificity and regulation of CD18-dependent adhesions. In *Leukocyte Adhesion Molecules: Structure, Function, and Regulation*. (Springer, T. A., Anderson, D. C., Rosenthal, A. S., and Rothlein, R., eds) pp. 190-207, Springer-Verlag, New York
- Lo, S. K., Van Seventer, G. A., Levin, S. M., and Wright, S. D. (1989) Two leukocyte receptors (CD11a/CD18) mediate transient adhesion to endothelium by binding to different ligands. *J. Immunol.* **143**, 3325-3329
- Figdor, C. G., Velde, A., and De Vries, J. E. (1989) The role of LFA-1 and related antigens in adhesion mediated functions of human monocytes. In *Leukocyte Adhesion Molecules: Structure, Function, and Regulation*. (Springer, T. A., Anderson, D. C., Rosenthal, A. S., and Rothlein, R., eds) pp. 159-169, Springer-Verlag, New York
- Dransfield, I., Cabanas, C., Craig, A., and Hogg, N. (1992) Divalent cation regulation of the function of the leukocyte integrin LFA-1. *J. Cell Biol.* **116**, 219-226
- Luscinskas, F. W., Kiely, J., Ding, H., Obin, M. S., Herbert, C. A., Baker, J. B., and Gimbrone, M. A., Jr. (1992) In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. *J. Immunol.* **149**, 2163-2171
- Zimmerman, G. A., Prescott, S. M., and McIntyre, T. M. (1992) Endothelial cell interactions with granulocytes: tethering and signaling molecules. *Immunol. Today* **13**, 93-100
- Rot, A. (1992) Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. *Immunol. Today* **13**, 291-294
- Gimbrone, M. A., Jr., Obin, M. S., Brock, A. F., Luis, E. A., Hass, P. E., Hebert, C. A., Yip, Y. K., Leung, D. W., Lowe, D. G., Kohr, W. J., Darbonne, W. C., Bechtol, K. B., and Baker, J. B. (1989) Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. *Science* **246**, 1601-1603
- Huber, A. R., Kunkel, S. L., Todd, R. F., III, and Weiss, S. J. (1991) Regulation of transendothelial neutrophil migration by endogenous interleukin-8. *Science* **253**, 1-4
- Yan, H., Juhasz, I., Pilewsky, J., Murphy, G. F., Herlyn, M., and Albelda, S. M. (1993) Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. *J. Clin. Invest.* **91**, 986-996
- Smith, C. W., Marlin, S. D., Rothlein, R., Toman, C., and Anderson, D. C. (1989) Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro. *J. Clin. Invest.* **83**, 2008-2017
- Huang, A. J., and Silverstein, S. C. (1992) Mechanisms of neutrophil migration across endothelium. In *Endothelial Cell Dysfunctions*. (Simionescu, N., and Simionescu, M., eds) pp. 201-231, Plenum Press, New York
- Rosengren, S., Olofsson, A. M., von Andrian, U. H., Lundgren-Akerlund, E., and Arfors, K. (1991) Leukotriene B<sub>4</sub>-induced neutrophil-mediated endothelial leakage in vitro and in vivo. *J. Appl. Physiol.* **71**, 1322-1330
- Luscinskas, F. W., Cybulsky, M. I., Kiely, J., Peckins, C. S., Davis, V. M., and Gimbrone, M. A., Jr. (1991) Cytokine-activated human endothelial monolayers support enhance neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. *J. Immunol.* **146**, 1617-1625
- Muller, W. A., Weigl, S. A., Deng, X., and Phillips, D. M. (1993) PECAM-1 is required for transendothelial migration of leukocytes. *J. Exp. Med.* **178**, 449-460
- DeLisser, H. M., Newman, P. J., and Albelda, S. M. (1993) Platelet endothelial cell adhesion molecule (CD31). In *Current Topics Microbiology and Immunology*, Vol. 184, *Leukocyte Homing and Differentiation* (Dunon, D., Mackay, C. R., and Imhof, B. A., eds) pp. 37-45, Springer-Verlag, Heidelberg
- Vaporciyan, A. A., DeLisser, H. M., Yan, H.-C., Mendiguren, I. I., Thom, S. R., Jones, M. L., Ward, P. A., and Albelda, S. M. (1993) Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. *Science* **262**, 1580-1582
- Tanaka, Y., Albelda, S. M., Horgan, K. J., Van Seventer, G. A., Shimizu, Y., Newman, W., Hallam, J., Newman, P. J., Buck, C. A., and Shaw, S. (1992) CD31 expressed on distinctive T cell subsets is a preferential amplifier of  $\beta_1$  integrin-mediated adhesion. *J. Exp. Med.* **176**, 245-253
- Huang, A. J., Manning, J. E., Bandak, T. M., Ratau, M. C., Hanser, K. R., and Silverstein, S. C. (1993) Endothelial cell cytosolic free calcium regulates neutrophil migration across monolayers of endothelial cells. *J. Cell Biol.* **120**, 1371-1380
- Anderson, D. C., Miller, L. J., Schmalstieg, F. C., Rothlein, R., and Springer, T. A. (1986) Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. *J. Immunol.* **137**, 15-27
- Buttrum, S. M., Hatton, R., and Nash, G. B. (1993) Selectin-mediated rolling of neutrophils on immobilized platelets. *Blood* **82**, 1165-1174
- Watson, S. R., Fennie, C., and Lasky, L. A. (1991) Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimera. *Nature (London)* **349**, 164-166
- Mulligan, M. S., Watson, S. R., Fennie, C., and Ward, P. A. (1993) Protective effects of selectin chimeras in neutrophil-mediated lung injury. *J. Immunol.* **151**, 6410-6417
- Mulligan, M. S., Paulson, J. C., De Frees, S., Zheng, Z.-L., Lowe, J. B., and Ward, P. A. (1993) Protective effects of oligosaccharides in P-selectin-dependent lung injury. *Nature (London)* **364**, 149-151
- Geng, J.-G., Moore, K. L., Johnson, A. E., and McEver, R. P. (1991) Neutrophil recognition requires a CA<sup>2+</sup>-induced conformational change in the lectin domain of GMP-140. *J. Biol. Chem.* **266**, 22313-22318
- Ross, L., Hassman, F., and Malony, L. (1992) Inhibition of molt-4-endothelial adherence by synthetic peptides from the sequence of ICAM-1. *J. Biol. Chem.* **267**, 8537-8543
- Etzioni, A., Frydman, M., Pollack, S., Avidor, I., Phillips, M. L., Paul-



- son, J. C., and Gershoni-Baruch, R. (1993) Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. *N. Engl. J. Med.* **327**, 1789-1792
43. von Andrian, U. H., Berger, E. M., Ramezani, L., Chambers, J. D., Ochs, H. D., Harlan, J. M., Paulson, J. C., Etzioni, A., and Arfors, K. (1993) In vivo behavior of neutrophils from two patients with distinct inherited leukocyte adhesion deficiency syndromes. *J. Clin. Invest.* **91**, 2893-2897
  44. Wilson, R. W., Ballantyne, C. M., Smith, C. W., Montgomery, C., Bradley, A., O'Brien, W. E., and Beaudet, A. L. (1993) Gene targeting yields a CD18-mutant mouse for study of inflammation. *J. Immunol.* **151**, 1571-1578
  45. Wolitzky, B., Kwee, L., Terry, R., Kontgen, F., Stewart, C., Rumberger, J. M., Burns, D. K., and Labow, M. A. (1994) Targeted disruption of the murine E-selectin and VCAM-1 genes. *J. Cell. Biochem. Suppl.* **18A**, 300
  46. Sligh, J. E., Jr., Ballantyne, C. M., Rich, S. S., Hawkins, H. K., Smith, C. W., Bradley, A., and Beaudet, A. L. (1993) Inflammatory and immune responses are impaired in ICAM-1 deficient mice. *Proc. Natl. Acad. Sci. USA* **90**, 8529-8533
  47. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., and Wagner, D. D. (1993) Leukocyte rolling and extravasation are severely compromised in P-selectin-deficient mice. *Cell* **74**, 541-554
  48. Mulligan, M. S., Varani, J., Dame, M. K., Lane, C. L., Smith, C. W., Anderson, D. C., and Ward, P. A. (1991) Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. *J. Clin. Invest.* **88**, 1396-1406
  49. Jutila, M. A., Rott, L., Berg, E. L., and Butcher, E. C. (1989) Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. *J. Immunol.* **143**, 3318-3324
  50. Ley, K., Gaehgans, P., Kennie, C., Singer, M. S., Lasky, L. A., and Rosen, S. D. (1991) Lectin-like cell adhesion molecule 1 mediates leukocyte rolling in mesenteric venules in vivo. *Blood* **77**, 2553-2555
  51. Gundel, R. H., Wegner, C. D., Torcellini, C. A., Clarke, C. C., Haynes, N., Rothlein, R., Smith, C. W., and Letts, L. G. (1991) Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway obstruction in monkeys. *J. Clin. Invest.* **88**, 1407-1411
  52. Yan, H.-C., DeLisser, H. M., Pilewski, J. M., Barone, K. M., Szklut, P. J., Chang, X.-J., Ahern, T. J., Langer-Safer, P., and Albelda, S. M. (1994) Leukocyte recruitment into human skin transplanted onto severe combined immunodeficient mice induced by tumor necrosis factor  $\alpha$  is dependent on E-selectin. *J. Immunol.* **152**, 3063-3063
  53. Mulligan, M. S., Polley, M. J., Bayer, R. J., Nunn, M. F., Paulson, J. C., and Ward, P. A. (1992) Neutrophil-dependent acute lung injury—requirement for P-selectin (GMP-140). *J. Clin. Invest.* **90**, 1600-1607
  54. Weyrich, A. S., Ma, X.-L., Lefler, D. J., Albertine, K. H., and Lefler, A. M. (1993) In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. *J. Clin. Invest.* **91**, 2620-2629
  55. Winn, R. K., Liggitt, D., Vedder, N. B., Paulson, J. C., and Harlan, J. M. (1993) Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. *J. Clin. Invest.* **92**, 2042-2047
  56. Doerchuk, C. M., Winn, R. K., Coxson, H. O., and Harlan, J. M. (1990) CD18-dependent and -independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits. *J. Immunol.* **144**, 2327-2333
  57. Winn, R. K., and Harlan, J. M. (1993) CD18-independent neutrophil and mononuclear leukocyte emigration into the peritoneum of rabbits. *J. Clin. Invest.* **92**, 1168-1173
  58. Mulligan, M. D., Varani, J., Warren, J. S., Till, G. O., Smith, C. W., Anderson, D. C., and Todd, R. F., III (1992) Roles of  $\beta_2$  integrins of rat neutrophils in complement- and oxygen radical-mediated acute inflammatory injury. *J. Immunol.* **148**, 1847-1857
  59. Mulligan, M. S., Warren, J. S., Smith, C. W., Anderson, D. C., Yeh, C. G., Rudolph, A. R., and Ward, P. A. (1992) Lung injury after deposition of IgA immune complexes. *J. Immunol.* **148**, 3086-3092
  60. Mulligan, M. S., Johnson, K. J., Todd, R. F., III, Issekutz, T. B., Miyasaka, M., Tamatani, T., Smith, C. W., Anderson, D. C., and Ward, P. A. (1993) Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. *J. Clin. Invest.* **91**, 577-587
  61. Mulligan, M. S., Smith, C. W., Anderson, D. C., Todd, R. F., III, Miyasaka, M., Tamatani, T., Issekutz, T. B., and Ward, P. A. (1993) Role of leukocyte adhesion molecules in complement-induced lung injury. *J. Immunol.* **150**, 2401-2406
  62. Mulligan, M. S., Wilson, G. P., Todd, R. F., Smith, C. W., Anderson, D. C., Varani, J., Issekutz, T. B., Miyasaka, M., Tamatani, T., Rusche, J. R., Vaporciyan, A. A., and Ward, P. A. (1993) Role of  $\beta_1$ ,  $\beta_2$  integrins and ICAM-1 in lung injury after deposition of IgG and IgA immune complexes. *J. Immunol.* **150**, 2407-2417
  63. Fischer, A., Griscelli, C., Blanche, S., LeDeist, F., Veber, F., Lopez, M., DeLaage, M., Olive, D., Mawas, C., and Janossy, G. (1986) Prevention of graft failure by an anti-HLA-1 monoclonal antibody in HLA-mismatched bone marrow transplantation. *Lancet* **2**, 1058-1061
  64. Haug, C. E., Colvin, R. B., Delmonico, F. L., Atuchincloss, H., Jr., Rolko-Rubin, N., Preffer, F. I., Rothlein, R., Norris, S., Scharshmidt, L., and Cosimi, A. B. (1993) A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. *Transplantation* **55**, 766-773
  65. Gamble, J. R., Skinner, M. P., Berndt, M. C., and Vadas, M. A. (1990) Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP140. *Science* **249**, 414-417
  66. Lobb, R. R., Chi-Rosso, G., Leone, D. R., Rosa, M. D., Bixler, S., Newman, B. M., Luhowskij, S., Benjamin, C. D., Gougas, I. G., Goelz, S. E., Hession, C., and Chow, E. P. (1991) Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1. *J. Immunol.* **147**, 124-129
  67. Fecondo, J. V., Kent, S. B. H., and Boyd, A. (1991) Inhibition of intercellular adhesion molecule 1-dependent biological activities by a synthetic peptide analog. *Proc. Natl. Acad. Sci. USA* **88**, 2879-2882
  68. DeLisser, H. M., Yan, H.-C., Newman, P. J., Muller, W. A., Buck, C. A., and Albelda, S. M. (1993) Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. *J. Biol. Chem.* **268**, 16037-16046
  69. Nelson, R. M., Dolich, S., Aruffo, A., Ceconi, O., and Bevilacqua, M. P. (1993) Higher-affinity oligosaccharide ligands for E-selectin. *J. Clin. Invest.* **91**, 1157-1166
  70. Bennett, C. F., Condon, T. P., Grimm, S., Chan, H., and Chiang, M.-Y. (1994) Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. *J. Immunol.* In press
  71. Bennett, C. F. (1994) Regulation of leukocyte-endothelial cell adhesion molecule expression with synthetic oligonucleotides. *J. Cell. Biochem. Suppl.* **18A**, 262
  72. Chopra, J., and Webster, R. O. (1988) PGE<sub>2</sub> inhibits neutrophil adherence and neutrophil-mediated injury to cultured endothelial cells. *Am. Rev. Resp. Dis.* **138**, 915-920
  73. Colgan, S. P., Serhan, C. N., Parkos, C. A., Delp-Archer, C., and Madara, J. L. (1993) Lipoxin A<sub>4</sub> modulates transmigration of human neutrophils across intestinal epithelial monolayers. *J. Clin. Invest.* **92**, 75-82
  74. Kubes, P., Suzuki, M., and Granger, D. N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc. Natl. Acad. Sci. USA* **88**, 4651-4655
  75. Cronstein, B. N., Levin, R. I., Philips, M., Hirschhorn, R., Abramson, S. B., and Weissmann, G. (1992) Neutrophil adherence to endothelium is enhanced via adenosine A<sub>1</sub> receptors and inhibited via adenosine A<sub>2</sub> receptors. *J. Immunol.* **148**, 2201-2206
  76. Booth, S. A., Moody, C. E., Dahl, M. V., Herron, M. J., and Nelson, R. D. (1992) Dapsone suppresses integrin-mediated neutrophil adherence function. *J. Invest. Dermatol.* **98**, 135-140
  77. Burch, R. M., Weitzberg, M., Blok, N., Muhlhauser, R., Martin, D., Farmer, S. G., Bator, J. M., Connor, J. R., Ko, C., Kuhn, W., McMillan, B. A., Raynor, M., Shearer, B. G., Tiffany, C., and Wilkins, D. E. (1991) N-Fluorenyl-9-methoxycarbonyl amino acids, a class of anti-inflammatory agents with a different mechanism of action. *Proc. Natl. Acad. Sci. USA* **88**, 355-359
  78. Burch, R. M., Noronha-Blob, L., Bator, J. M., Lowe, V. C., and Sullivan, J. P. (1993) Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge. *J. Immunol.* **150**, 3397-3403
  79. Kubes, P. (1993) Polymorphonuclear leukocyte-endothelium interactions: a role for pro-inflammatory and anti-inflammatory molecules. *Can. J. Physiol. Pharmacol.* **71**, 88-97
  80. Picker, L. J., and Butcher, E. C. (1992) Physiological and molecular mechanisms of lymphocyte homing. *Annu. Rev. Immunol.* **10**, 561-583